Associated Papers
Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine.
Richter S et al.
Endocrine-related Cancer, 2022
Interleukin-6 producing pheochromocytoma/paraganglioma: case series from a tertiary referral centre for pheochromocytomas and paragangliomas.
Meijs AC et al.
Journal of Endocrinological Investigation, 2021
Tumor multifocality with vagus nerve involvement as a phenotypic marker of SDHD mutation in patients with head and neck paragangliomas: A 18 F-FDOPA PET/CT study.
Amodru V et al.
Head & Neck, 2019
Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma.
Richter S et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2019
High prevalence of occult paragangliomas in asymptomatic carriers of SDHD and SDHB gene mutations.
Heesterman BL et al.
European Journal of Human Genetics : Ejhg, 2013
Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD.
Ricketts CJ et al.
Human Mutation, 2010
Mutations associated with succinate dehydrogenase D-related malignant paragangliomas.
Timmers HJ et al.
Clinical Endocrinology, 2008
Chromosome 11 monosomy in conjunction with a mutated SDHD initiation codon in nonfamilial paraganglioma cases.
Riemann K et al.
Cancer Genetics and Cytogenetics, 2004
Active succinate dehydrogenase (SDH) and lack of SDHD mutations in sporadic paragangliomas.
Braun S et al.
Anticancer Research, 0
Select a paper to view details